IM Cannabis (IMCC) Registration Filing summary

Company overview and business model

• Operates as an international medical cannabis provider, focusing on Israel and Germany, leveraging a data-driven approach and global supply chain to deliver high-quality products.

• Shifted strategic focus to Germany following partial legalization in April 2024, aiming for significant growth in the expanding medical cannabis market.

• Maintains strong presence in Israel through retail pharmacies, online platforms, and proprietary genetics, enhancing direct patient relationships and operational efficiency.

• German operations are anchored by a logistics center and EU-GMP production facility, enabling import, repackaging, and testing of cannabis products.

Financial performance and metrics

• As of June 30, 2025, pro forma cash position was C$12.6 million, with total capitalization reaching C$30.8 million after recent private placements and warrant exercises.

• Recent private placements in 2024 and 2025 raised aggregate gross proceeds of C$7.76 million, with warrant amendments extending expiration and reducing exercise prices.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling shareholders; proceeds from warrant exercises will be used for general working capital, debt repayment, and corporate purposes.